Physician profile
Lin Clark
NPI 1396830477
$2,349.71
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $343 · 2021: $1,201 · 2022: $401.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.44 | 2019-2021 | |
| Abbott Laboratories | $272.19 | 2022 | |
| Merck Sharp & Dohme LLC | $202.80 | 2020-2021 | |
| Amgen INC. | $167.69 | 2019-2021 | |
| Abbvie INC. | $161.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $154.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.11 | 2021-2022 | |
| Mylan Specialty L.P. | $113.05 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $110.16 | 2020-2022 | |
| Lilly USA, LLC | $93.44 | 2019-2021 | |
| Eisai INC. | $88.42 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $76.29 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $66.77 | 2019-2021 | |
| Amarin Pharma, INC. | $56.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $46.76 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.88 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $30.34 | 2021 | |
| Sanofi Pasteur INC. | $26.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.28 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $24.66 | 2021 | |
| Astellas Pharma US INC | $24.65 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $23.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.04 | 2021 | |
| Esperion Therapeutics, INC. | $18.94 | 2021 | |
| Hologic Sales and Service, LLC | $16.62 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.49 | 2021 | |
| Medtronic, INC. | $13.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.